Therefore, prospective validation in independent, multi-center cohorts is essential to confirm the generalizability of our observations and to further elucidate the prognostic and potential therapeutic implications of EVI1 expression in the context of modern, molecularly defined ALL therapy. This evidence concerns the gene RUNX1 and acute lymphoblastic leukemia.